HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
PCRX
Pacira BioSciences Inc
Healthcare Drug Manufacturers - Specialty & Generic · New Jersey, USA · Reports in usd
Market Cap: $1.05B
Market Cap
$1.05B
Enterprise Val
$1.23B
P/E Ratio
149.91
P/B Ratio
1.52
Trailing PEG (1Y)
-1.69
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$693.1M
Gross Margin79.53%
Profit Margin79.53%
Return on Equity0.95%
Return on Assets0.49%
Current Ratio4.54
Debt/Equity0.60
LT Debt/Equity0.59
Revenue Per Share4.58

Income Statement

Dec 31, 2025
Revenue$196.9M
Cost of Revenue$40.3M
Gross Profit$156.6M
R&D$37.5M
SG&A$101.6M
Operating Expenses$154.2M
Operating Income$2.3M
Interest Expense$3.9M
Tax Expense-$1.1M
Net Income$1.6M
EPS (Basic)$0.04
EPS (Diluted)$0.04
EBIT$4.5M
EBITDA$25.8M
Consolidated Income$1.6M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$158.5M
Accounts Receivable$124.1M
Inventory$152.9M
Current Assets$548.0M
LT Investments$22.3M
Property, Plant & Equipment$182.5M
Intangibles$388.3M
Non-Current Assets$716.9M
Total Assets$1.26B
Accounts Payable$15.2M
Current Debt$9.8M
Current Liabilities$120.6M
LT Debt$408.4M
Non-Current Liabilities$451.2M
Total Liabilities$571.8M
Total Debt$418.2M
Retained Earnings-$199.3M
Shareholder Equity$693.1M
Shares Outstanding43,021,275

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow$43.7M
Investing Cash Flow$19.3M
Financing Cash Flow-$51.7M
CapEx-$218.0K
Free Cash Flow$43.5M
Depreciation & Amort.$21.3M
Stock-Based Comp$13.5M
Acquisitions / Disposals$0.00
Investment Activity$19.6M
Debt Issued/Repaid-$5.0M
Equity Issued/Repaid-$46.5M
Dividends Paid$0.00
Net Change in Cash$11.0M
Data cached · Meta live · Daily live · Statements live · TTL 24h